Fudan Zhangjiang: The price reduction of Doxorubicin Liposome Injection is not less than 35%.
On April 30, Fudan Zhangjiang announced that the company decided to adjust the retail price of doxorubicin hydrochloride liposome injection market from May 1, 2025, with a price reduction of no less than 35% compared with the previous winning price. The annual sales revenue of the drug in 2024 will be approximately RMB210 million, accounting for 29% of the Company's annual sales revenue. It is expected that the price adjustment will adversely affect the company's sales revenue in 2025 and subsequent implementation periods, which may lead to the risk of a single product loss of the drug in 2025.
- 1